Host-based antipoxvirus therapeutic strategies: Turning the tables

Journal of Clinical Investigation

Volumn 115, Issue 2, 2005, Pages 231-233

  Fauci, Anthony S ^a   Challberg, Mark D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CANERTINIB; CIDOFOVIR; CYCLOSPORIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; INTEGRASE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; PROTEIN TYROSINE KINASE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS ANTIBODY; VIRUS PROTEIN; MORPHOLINE DERIVATIVE;

GENE DELETION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SMALLPOX; SMALLPOX VIRUS; VACCINATION; VACCINIA; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; BIOLOGICAL WARFARE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NOTE; PATHOLOGY; PHYSIOLOGY; PROTO ONCOGENE; VIRUS ACTIVATION;

BIOLOGICAL WARFARE; GENES, ERBB-1; HUMANS; MORPHOLINES; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SMALLPOX; VARIOLA VIRUS; VIRUS ACTIVATION;

EID: 14944376682     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200524270     Document Type: Review

References (22)

1. Lane, H.C., La Montagne, J., and Fauci, A.S. 2001. Bioterrorism: a clear and present danger. Nat. Med. 7:1271-1273.
2. [Anonymous]. 2002. NIAID biodefense research agenda for CDC category A agents. NIH Publication No. 03-5308. www.niaid.nih.gov/biodefense/ research/biotresearchagenda.pdf.
3. Mahy, B.W.J. 2003. An overview on the use of a viral pathogen as a bioterrorism agent: why smallpox? Antiviral Res. 57:1-5.
4. Smith, G.L., and McFadden, G. 2002. Smallpox: anything to declare? Nat. Rev. Immunol. 2:521-527.
5. Harrison, S.C., et al. 2004. Discovery of antivirals against smallpox. Proc. Natl. Acad. Sci. U. S. A. 101:11178-11192.
6. Ibarra, V., Blanco, J.R., Oteo, J.A., and Rosel, L. 2000. Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient, Acta Derm. Venereol 80:315-316.
7. Greene, W.C. 2004. The brightening future of HIV therapeutics. Nat. Immunol. 5:867-871.
8. Yang, H., et al. 2005. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest. 115:379-387. doi:10.1172/JCI200523220.
9. Kim, M., et al. 2004. Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies. J. Biol. Chem. 279:25838-25848.
10. Tzahar, E., et al. 1998. Pathogenic poxviruses reveal viral strategies to exploit the Erb B signaling network. EMBO J. 17:5948-5963.
11. Buller, R.M.L, Chakrabarti, S., Cooper, J.A., Twardzik, D.R., and Moss, B. 1988. Deletion of the vaccinia virus growth factor gene reduces virus virulence. J. Virol. 62:866-874.
12. Opgenorth, A., Nation, N., Graham, K., and McFadden, G. 1993. Transforming growth factor alpha, Shope fibroma growth factor, and vaccinia growth factor can replace myxoma growth factor in the induction of myxomatosis in rabbits. Virology. 192:701-709.
13. Smith, G.L., and Law, M. 2004. The exir of Vaccinia virus from infected cells. Virus Res. 106:189-197.
14. Newsome, T.P., Scaplehorn, N., and Way, M. 2004. Src mediates a switch from microtubule- to actin-based motility of Vaccinia virus. Science. 306:124-129.
15. Hall, A. 2004. Src launches vaccinia. Science. 306:65-67.
16. Yarden, Y., and Sliwkowski, M.X. 2001. Untangling the ErbB signalling network. Nut. Rev. Mol. Cell. Biol. 2:127-137.
17. Hooper, J.W., Custer, D.M., and Thompson, E. 2003. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology. 306:181-195.
18. Fogg, C., et al. 2004. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol. 78:10230-10237.
19. Rizzardi, C.P., et al. 2002. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J. Clin. Invest. 109:681-688. doi:10.1172/JCI200214522.
20. Chapuis, A.G., et al. 2000. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat. Med. 6:762-768.
21. Cockerill, G.S., and Lackey, K.E. 2002. Small molecule inhibitors of the class I receptor tyrosine kinase family. Curr. Top. Med. Chem. 2:1001-1010.
22. Wakeling, A.E, 2002. Epidermal growth factor receptor tyrosine kinase inhibitors. Curr: Opin. Pharmacol 2:382-387.